Fig. 5: Genomic alterations as determined by ctDNA. | Nature Medicine

Fig. 5: Genomic alterations as determined by ctDNA.

From: Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

Fig. 5

a, Landscape of genomic alterations in baseline ctDNAa. b, Relationships among ctDNA-detected alterations in key signal transduction genes (MET, EGFR, FGFR2, PIK3CA GoF, KRAS/NRAS), tumor mutation burden and ORR. aExcluding germline, putative clonal hematopoiesis of indeterminate potential and synonymous variants without annotations using OncoKB. Included any amplification type (focal and aneuploidy). Excluding two patients in exploratory cohorts because of missing HER2 test result. Highly frequent genes (≥15%) are shown. Patients were ordered by cohort, HER2 status, BOR and OS. bbTMB cutoff value was 20 mutations per megabase according to the Guardant Health OMNI platform. b, Error bars represent 95% CI. BOR, best overall response; MSI, microsatellite instability; PCHG, percentage change from baseline (tumor size by computed tomography scan).

Back to article page